Background: The purpose of this study was to find the factors that may be helpful for differentiating pancreatic cancer-associated diabetes mellitus (PC + DM) from common type 2 diabetes for the early diagnosis of pancreatic cancer. Methods: From January 2008 to August 2013, 171 patients with pancreatic cancer and new-onset diabetes were recruited for the study; 242 age- and gender-matched patients with common type 2 diabetes were also identified as control during the same period. The patient’s characteristics and laboratory parameters were compared between the 2 groups. Results: By multivariate logistic regression analysis, we found that body mass index (BMI), the age of onset of diabetes, hepatitis B virus (HBV) infection, total bilirubin (TBIL), alanine aminotransferase (ALT), creatinine (Cr), apolipoprotein-A1 (APO-A1), and white blood cell (WBC) were independent predictive factors for differentiating PC + DM from common type 2 diabetes; the areas under receiver operating characteristic curves were up to 0.815 for the combination of these 8 markers. Conclusions: These results suggest that BMI, the age of onset of diabetes, HBV infection, TBIL, ALT, Cr, APO-A1, and WBC are factors that could differentiate PC + DM from common type 2 ­diabetes and may be used for early diagnosis of pancreatic cancer.

Journal Section:
Original Paper
Keywords:
Pancreatic cancer, Diabetes, Pancreatic cancer-associated diabetes mellitus
1.
Siegel RL, Miller KD, Jemal A: Cancer statistics, 2015. CA Cancer J Clin 2015; 65: 5–29.
2.
David M, Lepage C, Jouve JL, et al: Management and prognosis of pancreatic cancer over a 30-year period. Br J Cancer 2009; 101: 215–218.
3.
Schneider G, Siveke JT, Eckel F, et al: Pancreatic cancer: basic and clinical aspects. Gastroenterology 2005; 128: 1606–1625.
4.
Nitecki SS, Sarr MG, Colby TV, et al: Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving? Ann Surg 1995; 221: 59–66.
5.
Egawa S, Takeda K, Fukuyama S, et al: Clinicopathological aspects of small pancreatic cancer. Pancreas 2004; 28: 235–240.
6.
De Souza AL, Saif MW: Diabetes and pancreatic cancer. JOP 2014; 15: 118–120.
7.
Moses AC, Knudsen LB, Svendsen CB, et al: Pancreatitis-diabetes-pancreatic cancer: summary of an NIDDK-NCI workshop. Pancreas 2014; 43: 657.
8.
Everhart J, Wright D: Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. JAMA 1995; 273: 1605–1609.
9.
Pannala R, Leirness JB, Bamlet WR, et al: Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology 2008; 134: 981–987.
10.
Chari ST, Leibson CL, Rabe KG, et al: Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. Gastroenterology 2008; 134: 95–101.
11.
Aggarwal G, Kamada P, Chari ST: Prevalence of diabetes mellitus in pancreatic cancer compared to common cancers. Pancreas 2013; 42: 198–201.
12.
American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes care 2007; 30(suppl 1):S42–S47.
13.
Neoptolemos JP, Stocken DD, Friess H, et al: A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004; 350: 1200–1210.
14.
Johnstone PA: NCI surveillance, epidemiology, and end results (SEER) registry. Curr Probl Cancer 2012; 36: 182.
15.
Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin 2011; 61: 69–90.
16.
Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A, et al: Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 2005; 92: 2076–2083.
17.
Permert J, Ihse I, Jorfeldt L, et al: Improved glucose metabolism after subtotal pancreatectomy for pancreatic cancer. Br J Surg 1993; 80: 1047–1050.
18.
Sah RP, Nagpal SJ, Mukhopadhyay D, et al: New insights into pancreatic cancer-induced paraneoplastic diabetes. Nat Rev Gastroenterol Hepatol 2013; 10: 423–433.
19.
Michaud DS, Giovannucci E, Willett WC, et al: Physical activity, obesity, height, and the risk of pancreatic cancer. JAMA 2001; 286: 921–929.
20.
Calle EE, Rodriguez C, Walker-Thurmond K, et al: Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003; 348: 1625–1638.
21.
Arslan AA, Helzlsouer KJ, Kooperberg C, et al: Anthropometric measures, body mass index, and pancreatic cancer: a pooled analysis from the pancreatic cancer cohort consortium (PanScan). Arch Intern Med 2010; 170: 791–802.
22.
Deurenberg P, Yap M, van Staveren WA: Body mass index and percent body fat: a meta analysis among different ethnic groups. Int J Obes Relat Metab Disord 1998; 22: 1164–1171.
23.
Hankin JH, Stram DO, Arakawa K, et al: Singapore Chinese health study: development, validation, and calibration of the quantitative food frequency questionnaire. Nutr Cancer 2001; 39: 187–195.
24.
Untawale S, Odegaard AO, Koh WP, et al: Body mass index and risk of pancreatic cancer in a Chinese population. PloS One 2014; 9:e85149.
25.
Pannala R, Leibson CL, Rabe KG, et al: Temporal association of changes in fasting blood glucose and body mass index with diagnosis of pancreatic cancer. Am J Gastroenterol 2009; 104: 2318–2325.
26.
Muniraj T, Chari ST: Diabetes and pancreatic cancer. Minerva Gastroenterologica e Dietologica 2012; 58: 331–345.
27.
Liao KF, Lai SW, Li CI, et al: Diabetes mellitus correlates with increased risk of pancreatic cancer: a population-based cohort study in Taiwan. J Gastroenterol Hepatol 2012; 27: 709–713.
28.
Mizuno S, Nakai Y, Isayama H, et al: Risk factors and early signs of pancreatic cancer in diabetes: screening strategy based on diabetes onset age. J Gastroenterol 2013; 48: 238–46.
29.
Iloeje UH, Yang HI, Jen CL, et al: Risk of pancreatic cancer in chronic hepatitis B virus infection: data from the REVEAL-HBV cohort study. Liver Int 2010; 30: 423–429.
30.
Berrington de Gonzalez A, Yun JE, Lee SY, et al: Pancreatic cancer and factors associated with the insulin resistance syndrome in the Korean cancer prevention study. Cancer Epidemiol Biomarkers Prev 2008; 17: 359–364.
31.
Ben Q, Li Z, Liu C, et al: Hepatitis B virus status and risk of pancreatic ductal adenocarcinoma: a case-control study from China. Pancreas 2012; 41: 435–440.
32.
Ryan DP, Hong TS, Bardeesy N: Pancreatic adenocarcinoma. N Engl J Med 2014; 371: 2140–2151.
33.
Tsai CW, Grams ME, Inker LA, et al: ­Cystatin C- and creatinine-based estimated ­glomerular filtration rate, vascular disease, and mortality in persons with diabetes in the U.S. Diabetes care 2014; 37: 1002–1008.
34.
Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell 2011; 144: 646–674.
35.
Swierczynski J, Hebanowska A, Sledzinski T: Role of abnormal lipid metabolism in development, progression, diagnosis and therapy of pancreatic cancer. World J Gastroenterol 2014; 20: 2279–2303.
36.
Grundy SM, Vega GL: Role of apolipoprotein levels in clinical practice. Arch Intern Med 1990; 150: 1579–1582.
37.
McKay CJ, Glen P, McMillan DC: Chronic inflammation and pancreatic cancer. Best Pract Res Clin Gastroenterol 2008; 22: 65–73.
38.
Whitcomb DC: Inflammation and Cancer V. Chronic pancreatitis and pancreatic cancer. Am J Physiol Gastrointest Liver Physiol 2004; 287:G315–G319.
39.
Kozak KR, Su F, Whitelegge JP, et al: Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics 2005; 5: 4589–1596.
40.
Ai J, Tan Y, Ying W, et al: Proteome analysis of hepatocellular carcinoma by laser ­capture microdissection. Proteomics 2006; 6:538–546.
© 2018 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2018
You do not currently have access to this content.